In delaying the progression of Alzheimer’s, Kisunla provides patients and their families with an “invaluable gift of time” according to its advocates. Anne White, the Executive Vice President spoke ...

Cognitive decline was assessed by a test that measures memory, thinking and daily functioning. Kisunla becomes the third amyloid-clearing Alzheimer's drug approved since 2021.

The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.In a press ...

Warnings - Kisunla can cause Amyloid-Related Imaging Abnormalities or "ARIA." This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

Kisunla, the brand name of donanemab, can be used for mild and early cases of Alzheimer‘s-caused dementia, The New York Times reported. The Wall Street Journal said that about 6 million ...

Kisunla is expected to be available in the coming weeks. The total cost of therapy varies by patient based on when they complete treatment (6 months: $12,522; 12 months: $32,000; 18 months: $48,696).

Kisunla is the second drug of its kind approved behind leqembi (generic name lecanemab). A third drug — Biogen’s Aduhelm — was taken off the market and discontinued.

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a key feature of Alzheimer's disease.

Kisunla is now the second Alzheimer’s drug of its kind approved, behind Leqmebi. A third drug — Biogen’s Aduhelm — was taken off the market earlier this year.

Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA approved the drug in July 2024. In the TRAILBLAZER-ALZ 6 study ...

Warnings - Kisunla can cause serious allergic and infusion-related reactions. Do not receive Kisunla if you have serious allergic reactions to donanemab-azbt or any of the ingredients in Kisunla.

Kisunla joins the market as one of the few treatments for Alzheimer's. It will now compete will compete with a treatment from Biogen (BIIB) and Japanese partner Eisai called Leqembi.